Effect of glucose and/or branched chain amino acid infusion on plasma amino acid imbalance in chronic liver failure. 1981

F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia

The characteristic amino acid pattern observed in chronic liver failure with high aromatic and low branched chain amino acid levels is considered to be consequent to increased muscle protein catabolism. The main catabolic stimulus has been attributed to hyperglucagonemia and to a reduced insulin/glucagon molar ratio. Intravenous administration of a solution containing branched chain amino acids and glucose to patients with chronic liver cirrhosis rapidly normalizes the plasma amino acid pattern. This effect may result from either a change in the insulin/glucagon ratio, induced by glucose, or from the anticatabolic influence of branched chain amino acids on muscle protein turnover. To discriminate between these two possibilities, a crossover study was carried out to determine the effect of a 24-hour infusion of either glucose alone, or glucose plus branched chain amino acids, in seven patients with chronic liver failure. Blood glucose, insulin, glucagon, free fatty acids, and amino acid levels were determined. Branched chain amino acids were much more effective than glucose (p less than 0.01) in decreasing the levels of aromatic amino acids. Conversely, the insulin, glucagon, and free fatty acid levels with glucose alone were not altered with the addition of branched chain amino acids. These findings suggest an anticatabolic effect of branched chain amino acids on muscle protein turnover and suggest that factors other than insulin and glucagon may be responsible for the characteristic plasma amino acid pattern present in chronic liver failure.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010288 Parenteral Nutrition The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously). Intravenous Feeding,Nutrition, Parenteral,Parenteral Feeding,Feeding, Intravenous,Feeding, Parenteral,Feedings, Intravenous,Feedings, Parenteral,Intravenous Feedings,Parenteral Feedings
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
July 1991, Journal of hepatology,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
November 1981, The Journal of trauma,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
December 1983, Kidney international. Supplement,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
January 1990, Nutrition (Burbank, Los Angeles County, Calif.),
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
December 1983, Gastroenterologia Japonica,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
April 1978, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
November 1981, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
January 1983, Hepatology (Baltimore, Md.),
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
May 1998, Pharmacology, biochemistry, and behavior,
F Rossi-Fanelli, and M Angelico, and C Cangiano, and A Cascino, and R Capocaccia, and D DeConciliis, and O Riggio, and L Capocaccia
January 2012, Journal of clinical biochemistry and nutrition,
Copied contents to your clipboard!